A Study to Evaluate Avastin in Patients Treated in a Previous Genentech-Sponsored Cancer Study
Status:
Completed
Trial end date:
2004-07-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, open-label extension study. Subjects who have received rhuMAb VEGF
therapy in Study AVF2107g, AVF2119g, or AVF2192g and who completed the parent study are
eligible for inclusion in this trial. Subjects who have received placebo in Study AVF2107g or
AVF2192g are also eligible.